Deutsch English Français

Contact

EP3227686

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3227686

EP3227686 - MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 26.06.2020 Database last updated on 31.08.2024
Former	Examination is in progress Status updated on 04.06.2019
Former	Request for examination was made Status updated on 08.09.2017
Former	The international publication has been made Status updated on 30.06.2017
Most recent event Tooltip	26.06.2020	Application deemed to be withdrawn	published on 29.07.2020 [2020/31]
Applicant(s)	For all designated states Ignyta, Inc. 11111 Flintkote Avenue San Diego, CA 92121 / US
	[2017/41]
Inventor(s)	01 / CHRISTIANSEN, Jason, Hans 371D Pine Avenue Carlsbad, CA 92008 / US
	02 / MURPHY, Danielle, Anthea 752 Stevens Avenue Solana Beach, CA 92075 / US
	03 / BOOMER, Aaron, Scott 743 Sunset Drive Vista, CA 92081 / US
	04 / LAMOUREUX, Jennifer, Lyn 353 Aspen Creek Way Oceanside, CA 92057 / US
	[2017/41]
Representative(s)	HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB
	[N/P]
Former [2017/41]	HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB
Application number, filing date	15864500.2	01.12.2015
	[2017/41]
	WO2015US63163
Priority number, date	US201462086921P	03.12.2014 Original published format: US 201462086921 P
	[2017/41]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016089853
	Date:	09.06.2016
	Language:	EN
	[2016/23]
	Type:	A1 Application with search report
	No.:	EP3227686
	Date:	11.10.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.06.2016 takes the place of the publication of the European patent application.
	[2017/41]
Search report(s)	International search report - published on:	US	09.06.2016
	(Supplementary) European search report - dispatched on:	EP	26.07.2018
Classification	IPC:	G01N33/574, A61P35/00, A61K31/496, C12Q1/6813, C12Q1/686, G01N27/447	[2018/35]
	CPC:	G01N33/57484 (EP,US); A61K31/496 (EP,US); A61P35/00 (EP); C12Q1/6813 (US); C12Q1/686 (US); G01N27/447 (US); (+) G01N33/57411 (US); G01N33/57415 (US); G01N33/57423 (US); G01N33/57449 (US); G01N2800/52 (EP,US); G01N2800/7028 (US); G01N33/57438 (EP,US) (-)
	Former IPC [2017/41]	G01N33/574, A61P35/00, A61K31/496
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/41]
Title	German:	MULTIPLEXIERTE IMMUNHISTOCHEMIE-ASSAYS ZUR DIAGNOSE UND BEHANDLUNG VON KREBS	[2017/41]
	English:	MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER	[2017/41]
	French:	ANALYSES D'IMMUNOCYTOCHIMIE MULTIPLEXÉES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UN CANCER	[2017/41]
Entry into regional phase	29.06.2017	National basic fee paid
	29.06.2017	Search fee paid
	29.06.2017	Designation fee(s) paid
	29.06.2017	Examination fee paid
Examination procedure	29.06.2017	Examination requested [2017/41]
	29.06.2017	Date on which the examining division has become responsible
	25.02.2019	Amendment by applicant (claims and/or description)
	07.06.2019	Despatch of a communication from the examining division (Time limit: M06)
	18.12.2019	Application deemed to be withdrawn, date of legal effect [2020/31]
	24.01.2020	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2020/31]
Fees paid	Renewal fee
	21.12.2017	Renewal fee patent year 03
	19.12.2018	Renewal fee patent year 04
	10.12.2019	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XY]WO2009013126 (NERVIANO MEDICAL SCIENCES SRL [IT], et al) [X] 1-3,5-14 * page 5 * * page 19, lines 1-2 * * page 85, line 15 - page 86, line 6 * * page 13, lines 19-20; compound 11 * * page 22, lines 5-7 * * pages 75,99 * [Y] 15;
		[XP]WO2015124697 (IGNYTA INC [US], et al) [XP] 1-3,5-15 * paragraphs [0036] , [0040] - [0043] * * page 41, paragraphs 248,249 *;
		[E]WO2016089760 (IGNYTA INC [US]) [E] 1-3,5-15 * paragraphs [0011] , [0014] - [0016] * * paragraphs [0063] - [0065] *;
		[Y]WO2012019132 (CELL SIGNALING TECHNOLOGY INC [US], et al) [Y] 15 * paragraphs [0009] , [0013] , [0022] , [0 27] *;
		[XP]WO2015157624 (SLOAN KETTERING INST CANCER [US]) [XP] 1,3,5,7-11,14 * page 2, lines 1-21 * * page 5, line 26 - page 6, line 18 * * page 7, line 21 - page 8, line 25 * * pages 7,32 *;
		[XI] - Elena Ardini ET AL, "A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models \| Cancer Research", Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009, (20090418), page Abstract #3737, URL: http://cancerres.aacrjournals.org/content/69/9_Supplement/3737, (20180711), XP055491721 [X] 1,3,6,10-13,15 * abstract * [I] 5,7-9,14
		[XI] - Ardini Ardini ET AL, "Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models \| Molecular Cancer Therapeutics", Mol Cancer Ther 2009;8(12 Suppl):A244., (20091115), page Abstract A243, URL: http://mct.aacrjournals.org/content/8/12_Supplement/A244, (20180711), XP055491735 [X] 1,3,6,10-13,15 * abstract * [I] 5,7-9,14
		[XI] - Elena Ardini ET AL, "In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. \| Molecular Cancer Therapeutics", Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics: AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A232, (20111112), page Abstract A232, URL: http://mct.aacrjournals.org/content/10/11_Supplement/A232, (20180711), XP055491739 [X] 1,3,10,11,14,15 * abstract * [I] 9
		[XI] - Elena Ardini ET AL, "The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models.", Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2092, (20130406), page Abstract 2092, URL: http://cancerres.aacrjournals.org/content/73/8_Supplement/2092, (20180711), XP055491741 [X] 1,3,6,10-15 * abstract * [I] 5,7-9
		[XI] - Filippo G De Braud ET AL, "Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.: Journal of Clinical Oncology: Vol 32, No 15_suppl", ournal of Clinical Oncology 32, no. 15_suppl (May 20 2014) 2502-2502, (20140520), URL: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2502, (20180711), XP055491745 [X] 1,3,6,14,15 * abstract * [I] 5,7-13
		[XI] - ARDINI E ET AL, "NMS-E628, a potent and orally available small molecule inhibitor of anaplastic lymphoma kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, doi:10.1016/S1359-6349(10)71875-9, ISSN 1359-6349, (20101101), page 59, (20101101), XP027497858 [X] 1,3,6,14,15 * abstract * [I] 5,7-13 DOI: http://dx.doi.org/10.1016/S1359-6349(10)71875-9
		[XI] - David Anderson ET AL, "Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-10", EORTC-NCI-AACR 2014, (20141101), page abstract 310, URL: https://ignyta.com/wp-content/uploads/2016/10/Anderson-et-al_EORTC-2014.pdf.pdf, (20180711), XP055491752 [X] 1,3,5-7,10-15 * abstract * [I] 8,9
	International search	[Y]WO2014046730 (VENTANA MED SYST INC [US]) [Y] 1-32 * ; page 2, lines 1-20; page 5, lines 1-10; page 8, lines 1-6; page 11, lines,15-35; page 12, lines 1-15; page 18, lines 29-33; page 19, lines 1-35 *;
		[Y]WO2013174876 (NERVIANO MEDICAL SCIENCES SRL [IT]) [Y] 1-32 * ; page 1 paragraph 1, page 2 paragraph 3 *;
		[Y]US2013303461 (IAFRATE ANTHONY JOHN [US], et al) [Y] 6, 23/6 * ; paragraphs [0017]-[0019] *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p